Affinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study that ...

Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific ...

A revolutionary AI-powered diagnostic test for chronic obstructive pulmonary disease (COPD) is set to be introduced in GP surgeries across England from 14 April, offering a faster and more accurate ...

If you think smoking is the only threat to your lungs, think again. Rising air pollution, occupational hazards, lifestyle choices, and, of course, smoking all put a significant strain on respiratory ...

A multicenter prospective study validated that an electronic nose (eNose) can accurately detect lung cancer in individuals with suspected disease. In the validation cohort, a new eNose model achieved ...

With a San Antonio biotech firm’s test, your phlegm could help save you from cancer. The screening method developed by bioAffinity Technologies Inc. uses AI-aided computer analysis of a patient’s ...

Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...

Lung cancer accounts for 1 in 5 cancer-related deaths in the United States. While doctors say lung cancer is often treatable if caught early, millions of Americans who should be getting screened for ...

Affinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a ...

Lung cancer is the second most common cancer in the United States and is the leading cause of death from cancer. If lung cancer is found early, when it is small and before it has spread, it is more ...

Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations ...